DiaMedica Therapeutics Inc. (DMAC)

Market: NMS | Currency: USD

Address: 301 Carlson Parkway

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. Show more

📈 DiaMedica Therapeutics Inc. Historical Chart

📊 Statistics

Analyst 1 Year Price Target: $15.50
Upside/Downside from Analyst Target: 82.14%
Broker Call: 10
Dividend Minimum 3 Year Yield: 0.00%
EPS Growth Range (1Y): <0%
Net Income Growth Range (1Y): <0%
Revenue Growth Range (1Y): -
Upcoming Earnings Date: 2026-05-13
EPS Estimate: -0.18

💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for DiaMedica Therapeutics Inc.

Date	Reported EPS
2026-05-12 (estimated upcoming)	-
2026-03-30	-0.17
2025-11-12	-0.17
2025-08-12	-0.18
2025-05-13	-0.18
2025-03-17	-0.18
2024-11-13	-0.15
2024-08-07	-0.13
2024-05-08	-0.14
2024-03-19	-0.14
2023-11-13	-0.12
2023-08-14	-0.16
2023-05-15	-0.2
2023-03-28	-0.14
2022-11-09	-0.12
2022-08-10	-0.13
2022-05-04	-0.13
2022-03-14	-0.11
2021-11-10	-0.18
2021-08-11	-0.17
2021-05-05	-0.19
2021-03-10	-0.23
2020-11-04	-0.19
2020-08-11	-0.17
2020-05-13	-0.19

📰 Related News & Research

No related articles found for "diamedica therapeutics".